Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 75Genitourinary 29Breast 25Gastrointestinal 20Thoracic 13Tumor-Agnostic 12CNS 12Other solid neoplasm 11Sarcoma 7Head & Neck 6Dermatologic 4Lymphoid 2Other hematologic neoplasm 1Endocrine 1Classical hematology 1

Conditions

Thrombocytopenia 1Recurrence 1Ovarian Neoplasms 1Neutropenia 1Fallopian Tube Neoplasms 1Anemia 1

Interventions

Cyclophosphamide 93fludarabine phosphate 86Busulfan 63Cyclosporine 57Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53Epoetin Alfa 53Antilymphocyte Serum 43fludarabine 42Filgrastim 41Cytarabine 41Tacrolimus 39Melphalan 38Darbepoetin alfa 38Methotrexate 34Radiotherapy 32Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23Methylprednisolone 21Etoposide 21apixaban 18eltrombopag 16Thiotepa 16Dalteparin 16ferric carboxymaltose 14Daunorubicin 14Azacitidine 14Alemtuzumab 14thymoglobulin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × niraparib × Classical hematology × Clear all
NCT03891576 2025-01-17

Newton

Mario Negri Institute for Pharmacological Research

Phase 2 Terminated
83 enrolled
Classical hematologyGynecologic

Anemia, Fallopian Tube Neoplasms, Neutropenia, Ovarian Neoplasms, Recurrence, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡